Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy
Cheng Huang, Hongjian Li, Yunyu Feng, Xiaoling Li, Zongliang Zhang, Caiying Jiang, Jichao Wang, Yang Chen-li, Yuying Fu, Min Mu, Shasha Zhao, Zeng Wang, Yi Kuang, Huan Hou, Yuelong Wang, Wenhao Guo, Jianguo Xu, Hui Yang, Liangxue Zhou, Aiping Tong, Gang Guo
Abstract
Overall, our study indicates that combination therapy with sorafenib and B7H3×CD3 BiTE may be a new therapeutic option for the further study of preclinical treatment of OC.
Topics & Concepts
Bispecific antibodySorafenibAntibodyMedicineCancer researchAntibody therapyPharmacologyMonoclonal antibodyChemistryImmunologyHepatocellular carcinomaNanoparticle-Based Drug DeliveryPeptidase Inhibition and AnalysisCancer Research and Treatments